EP517 Cost-effective improvement in endometrial cancer diagnosis by the incorporation of molecular analysis: prospective pilot study. (1st November 2019)

• Record Type: Journal Article
• Authors: Fernandez-Gonzalez, S; Amoros, M; Arroyuelo, SM; Barazi, D; Cararach, M; Fernandez, J; Fernandez de Castillo, L; Jofre, L; Pallares, L; Palau, M; Rodriguez-Domingo, MJ; Santos, L; Sanz, X; Fernandez-Montoli, ME; Tena, G; Ponce, J
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A318
• Page End: A320
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.575
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The histopathology remains the gold standard to diagnose endometrial cancer (EC) from endometrial biopsy. Molecular tests have recently emerged as a useful tool to classify EC according to its prognosis. However, there is currently no published protocol that includes molecular diagnosis of postmenopausal women with abnormal uterine bleeding (AUB). We hypothesized that the incorporation of a molecular test in the management of postmenopausal women with AUB improves the cost-efectiveness of the diagnostic process. Methodology: We present a prospective study performed in postmenopausal women who presented AUB between 2009–2014. Seven centers recruited the patients. Three of them follow the classical diagnosis algorithm (group 1) and four centers follow the one that incorporates a molecular test (Gynecâ-Dx) performed on the remnants of aspirates (group 2). In group 2, when both the endometrial biopsy and the molecular test were negative, the consequent explorations were considered as 'out of procotol'. Clinical data, number of biopsies, ultrasounds, hysteroscopies and visits were compared between groups. In addition, the sensitivity (S), specificity (E), positive and negative predictive values (PPV and NPV) of the molecular test were calculated. Results: 94 patients were recruited. 51 vs 43 women were included in the classical and the molecular algorithm respectively. There were no differences in age, BMI, parity, use of tamoxifen or hormonal treatment. The detailed outcomes of explorations between classical vs molecular group are shown in table 1. 324 vs 229 explorations were performed respectively (table 2). In the molecular group, 92 explorations were considered 'out of protocol'. The test validations showed a 100% S, 92.5% E, 50% PPV and 100% NPV. Conclusion: According to our results, the incorporation of a molecular test for diagnosing EC in postmenopausal women who complained with AUB reduces the number of explorations. Consequently, the molecular algorithm might be more cost-effective than conventional algorithms. Disclosure: Nothing to disclose.